Skip to content
EmergingResearch compoundReference only

Flmodafinil

Experimental wakefulness-promoting compound, a relative of modafinil, known mainly from animal studies and barely studied in people.

NootropicEugeroicStimulantEugeroicStimulantFocusDopamineNorepinephrineAnti-fatigue
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassEugeroic · Stimulant · Focus
Primary targetDopamine transporter (DAT), atypical weak inhibitor
Targets3 receptor targets
EvidenceReference only
Affected systemsDopamineNorepinephrineAnti-fatigue

Contents

DETAILED OVERVIEW

What is Flmodafinil?

Flmodafinil (also known as CRL-40,940 or lauflumide) is a modified relative of modafinil, a wakefulness-promoting medicine. It is an experimental substance: it is not approved as a medicine anywhere, it is sold as a research chemical, and in the United Kingdom the Psychoactive Substances Act bans it.

It weakly blocks the reuptake of dopamine, a brain messenger, into nerve cells, and it indirectly switches on other brain pathways that affect wakefulness. In animal studies it was found to be about three times stronger than the original drug, but it has hardly been studied in people, so its long-term safety is unknown. The most common side effect is headache; insomnia, anxiety, restlessness and digestive complaints can also occur, and serious skin reactions rarely occur in this drug family. It may reduce the effectiveness of hormonal contraceptives, and its safety in pregnancy and breastfeeding has not been established.

Mechanism

Modafinil-like, DAT inhibition

Half-life

Limited human data

Legal status

Investigational, not approved

Receptor profile

  • Dopamine transporter (DAT)Strong
  • Norepinephrine transporter (NET)Weak
  • Orexin/histamine systemModerate

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Headache, the most common modafinil-class side effect
  • Insomnia, disrupted sleep, especially with late dosing (though milder than with Modafinil)
  • Anxiety, nervousness, restlessness
  • Appetite loss, nausea, mild GI discomfort
  • Dry mouth, dizziness
  • Mildly elevated heart rate or blood pressure (fewer adrenergic effects than Modafinil)
  • Rare but serious skin reaction risk in this class (rash, Stevens-Johnson syndrome)

Contraindications · 6

  • Pregnancy and breastfeeding: safety not established, avoid
  • Cardiovascular disease, arrhythmia, uncontrolled hypertension: caution due to dopaminergic/stimulant profile
  • History of anxiety disorders: may worsen anxiety and restlessness
  • Hormonal contraception: the modafinil class may reduce its efficacy (backup method advised)
  • Prior serious skin reaction (rash, hypersensitivity) to modafinil-type agents: contraindicated
  • Experimental, unapproved compound with limited human data; extra caution with hepatic or renal impairment

Related Nootropics

Same therapeutic category

FAQ

FAQ

Flmodafinil is a chemically modified relative of Modafinil that animal studies found to be roughly three times more potent than the original. There is essentially no human research on it, so it's best understood as an experimental wakefulness and focus compound rather than an established, well-studied nootropic. What is known comes mostly from animal models and anecdotal reports, not clinical trials.

Telegram

Have a question about Flmodafinil?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC15H13F2NO2S
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.